Journal profile · Oncology
Clinical Colorectal Cancer
ISSN 1533-0028 · eISSN 1938-0674 · Elsevier · UNITED STATES · Bimonthly · Founded 2001
Clinical Colorectal Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.55; hybrid open access; APC about USD 3,690; median 94 days to acceptance (97 articles, last 24 months); community-reported acceptance: fairly easy; 57 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Colorectal Cancer is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments and Colorectal and Anal Carcinomas, together about 47.6% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Colorectal Cancer is devoted to manuscripts that focus on early detection/screening, diagnosis, prevention, and treatment of colorectal cancer and other GI cancers, including pancreatic, liver, gastric/gastroesophageal, biliary, and other gastrointestinal cancers. The major emphasis is on recent scientific developments and original peer-reviewed manuscripts. Specific areas of interest include original reports on clinical research and/or translational research and translational correlative science that is directly related to clinical trials, in all (multidisciplinary) therapeutic fields that relate to colorectal cancer and other GI cancers.Further areas of interest include original research on drug sensitivity and resistance to cytotoxic agents, targeted therapies, immunotherapies, and other novel therapeutic approaches; pathology, (validated) predictive markers, and prognostic indicators; chemoprevention strategies; and integration of various therapeutic and multidisciplinary approaches. A much lower priority will be given to meta-analyses, pooled analyses, and real-world analyses unless the knowledge gained from such reports is significant and can be applied to clinical practice. In addition, unsolicited reviews are not encouraged unless there has been a discussion with the editor or deputy editors as the journal wants to ensure that reviews will provide real added value and true gain of knowledge.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Sharlene GillPublisher website
Editorial board by country: 5 in mainland China (about 11%); most named United States 19, Mainland China 5, Belgium 4, Canada 3, United Kingdom 2 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Colorectal Cancer Treatments and StudiesMedicine25.8%
- Colorectal Cancer Surgical TreatmentsMedicine14.3%
- Colorectal and Anal CarcinomasMedicine7.5%
- Gastric Cancer Management and OutcomesMedicine6.6%
- Genetic factors in colorectal cancerMedicine6.4%
- Cancer Treatment and PharmacologyMedicine6.1%
- Colorectal Cancer Screening and DetectionMedicine5.1%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.55LetPub ·
- Impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 5.5LetPub ·
- CiteScore (publisher)
- 5.5Publisher website ·
- SJR 2026-06
- 0.98LetPub ·
- SNIP 2026-06
- 0.83LetPub ·
- h-index
- 45LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 893OpenAlex ·
- 2-year mean citedness
- 1.56OpenAlex ·
- Self-citation rate
- 3.7%LetPub ·
- Share of gold OA articles
- 20.67%LetPub ·
Volume
- Articles per year
- 55LetPub ·
Articles by year OpenAlex count · 1,705 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 22 | 4 |
| 2025 | 57 | 20 | 54 |
| 2024 | 66 | 24 | 201 |
| 2023 | 57 | 25 | 221 |
| 2022 | 70 | 30 | 822 |
| 2021 | 84 | 28 | 963 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
94 daysMedian, submission to acceptance · P25–P75 55 days – 210 days
- Acceptance to online
- median 6 days (97 articles)
- Submission to online
- median 102 days
- Sample
- 97 articles with submission and acceptance dates (120 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 50 daysPublisher website ·
- Submission to acceptance
- 85 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,690 / EUR 3,450 / GBP 2,950 / JPY 457,670 | — | — | |
| Publisher website | USD 4,070 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5, with length limits
- case reportpotential impact on clinical practice. Case Reports should be 500–1,500 words in length. Case Series may be up to 3,000 words. Manuscriptmain text ≤ 1,500 words
- editorialOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- letterbe published together. Article Format: Letters should be 500–1,000 words in length, do not include figures or tables, and contain upmain text ≤ 1,000 words
- reviewOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- review articleOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of one reviewer for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Rea…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1533-0028
- Electronic ISSN
- 1938-0674
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Clinical Colorectal Cancer
What CAS zone is Clinical Colorectal Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Colorectal Cancer is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Colorectal Cancer?
The latest impact factor listed by LetPub is 2.55; CiteScore 5.5, h-index 79.
How long does peer review take at Clinical Colorectal Cancer?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 94 days (interquartile range 55–210 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Clinical Colorectal Cancer based?
Of the 44 board members whose country the journal's board page names, 5 (about 11%) are in mainland China; the countries named most often are United States (19), Mainland China (5) and Belgium (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Colorectal Cancer?
According to LetPub and DOAJ records, Clinical Colorectal Cancer is indexed in SCIE and Scopus.
Is Clinical Colorectal Cancer open access, and what is the APC?
Clinical Colorectal Cancer is a hybrid journal. For open-access publication: APC about USD 3,690.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .